Skip to content
drillr.ai
Sign up

02595.HK

GenFleet Therapeutics (Shanghai) Inc.

HKSE · Healthcare · Biotechnology · CN

HKD 22.50
−9.86%
Ask drillr

  • Oct 26, 2026, 02:37 UTC

    Genfleet Therapeutics (Shanghai), Inc. reported preliminary GFH276 dose-escalation data in previously treated RAS-mutant solid tumors, including partial responses from 40 mg once daily and no dose-limiting toxicities at 40–160 mg once daily without prophylactic medication.

    Source:

  • Oct 15, 2026, 00:10 UTC

    Jiangsu Hengrui? announced positive preliminary efficacy and safety results from its domestic GFH375 combination study in previously treated colorectal cancer and first-line pancreatic ductal adenocarcinoma.

    Source:

  • Oct 9, 2026, 00:49 UTC

    Jiangsu Hengrui? repurchased 135,000 shares at HK$27.80–HK$28.74 per share for approximately HK$3.8307 million.

    Source:

  • Oct 8, 2026, 04:12 UTC

    Hong Kong-listed shares showed mixed moves at the half-day close, with H&H International Holdings, JNBY Design Ltd. and Chervon Holdings Ltd. reaching record highs.

    Source:

  • Sep 23, 2026, 00:06 UTC

    GenFleet Therapeutics' overseas partner Verastem Oncology will hold an online investor call on October 14 to present overseas clinical development progress for GFH375/VS-7375.

    Source:

  • Sep 23, 2026, 00:06 UTC

    GenFleet Therapeutics announced it will hold an online investor call on October 15 to release preliminary clinical data for GFH375 (a KRAS G12D inhibitor) combined with cetuximab in KRAS G12D-mutant solid tumors.

    Source:

  • Sep 23, 2026, 00:06 UTC

    GenFleet Therapeutics will hold an online investor call on October 25 to further interpret the on-site oral presentation data for GFH276.

    Source:

  • Sep 23, 2026, 00:06 UTC

    GenFleet Therapeutics' GFH276 (a Pan RAS inhibitor) monotherapy preliminary clinical data for RAS-mutant solid tumors was selected as a Late-Breaking Abstract for the 2026 ESMO Annual Meeting in Madrid.

    Source:

  • Sep 22, 2026, 00:26 UTC

    China's National Medical Products Administration Center for Drug Evaluation proposed including GenFleet Therapeutics' clinical project GFH375 combined with cetuximab in the Breakthrough Therapy Designation list for KRAS G12D-mutant metastatic colorectal cancer.

    Source:

  • Sep 10, 2026, 23:06 UTC

    GenFleet Therapeutics (02595) repurchased 80,000 of its own shares for HK$2.063 million at HK$25.32-26 per share on September 10, 2026.

    Source:

  • Aug 26, 2026, 00:22 UTC

    GenFleet Therapeutics announced that its oral KRAS G12D inhibitor GFH375 has entered a Phase II study as first-line treatment for advanced non-small cell lung cancer with KRAS G12D mutation.

    Source:

  • Aug 21, 2026, 04:06 UTC

    GenFleet Therapeutics (B) reported interim results for the six months ended June 2026, with revenue of RMB 42.47 million, down 52.1% year-on-year, and a narrowed net loss of RMB 220 million versus RMB 699 million a year earlier.

    Source:

  • Aug 10, 2026, 00:33 UTC

    GenFleet Therapeutics announced that its oral KRAS G12D inhibitor GFH375 has initiated a registrational Phase III clinical study for non-small cell lung cancer, with the first patient enrolled at Nanjing Drum Tower Hospital.

    Source: